{"id":"W2082863510","doi":"10.1111/j.1365-2141.2012.09232.x","title":"An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib","year":2012,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"Onyx Pharmaceuticals; Exelixis; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Carfilzomib; Medicine; Bortezomib; Nausea; Refractory (planetary science); Proteasome inhibitor; Adverse effect; Multiple myeloma; Internal medicine; Regimen; Phases of clinical research; Oncology; Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00166,0.002001554,0.00289105,0.0005814714,0.0004023579,0.0008227261,0.0008294844,0.001516274,0.00367156],"category_scores_gemma":[0.001124291,0.0008051298,0.001581057,0.0003422274,0.0009401924,0.001036802,0.0003429841,0.003192744,0.0008051329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00066138,"about_ca_system_score_gemma":0.001198023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009321714,"about_ca_topic_score_gemma":0.0020297,"domain_scores_codex":[0.9995126,0.0002266409,0.00001766433,0.00009564083,0.00003990665,0.000107609],"domain_scores_gemma":[0.9991767,0.0001643668,0.0001181732,0.00005958804,0.0000443733,0.0004367767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8158861,0.1024543,0.002772605,0.0004324134,0.0009992564,0.0002187384,0.0002285561,0.00177907,0.02342484,0.000149584,0.001865996,0.04978849],"study_design_scores_gemma":[0.5374514,0.4526379,0.006070452,0.00001318961,0.0002082294,0.0001061717,0.00002463921,0.001082895,0.001206097,0.00009759338,0.001080173,0.00002126483],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938592,0.001441296,0.0004510354,0.0003678326,0.0001546181,0.001880838,0.0005715466,0.00009585379,0.001177755],"genre_scores_gemma":[0.9895945,0.001427322,0.001364667,0.0007174,0.000304323,0.002683616,0.001498594,0.0000234805,0.002386212],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00367156,"threshold_uncertainty_score":0.01228261,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04593809647162775,"score_gpt":0.3300050320972898,"score_spread":0.284066935625662,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}